Company Overview of EPIX Pharmaceuticals, Inc.
EPIX Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics through the use of its proprietary silico drug discovery technology to treat diseases of the central nervous system and lung conditions. Its therapeutic product candidates in development PRX-08066, a small-molecule inhibitor that completed Phase II clinical trials for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with chronic obstructive pulmonary disease; and PRX-07034, which completed Phase I studies for the treatment of cognitive impairment associated with schizophrenia. The company also offers Vasovist, an injectable intravascular cont...
4 Maguire Road
Lexington, MA 02421
Founded in 1988
Key Executives for EPIX Pharmaceuticals, Inc.
Senior Vice President of Regulatory Affairs & Quality
Vice President of Discovery & Business Development
Vice President of Corporate Relations
Executive Director of Clinical Research
Compensation as of Fiscal Year 2013.
EPIX Pharmaceuticals, Inc. Key Developments
SEC Revokes Registration Of Registered Securities of EPIX Pharmaceuticals
Oct 31 12
On October 29, 2012, the Securities and Exchange Commission (SEC) revoked the registration of each class of registered securities of EPIX Pharmaceuticals, Inc. (EPIX) for failure to make required periodic filings with the Commission. Without admitting or denying the findings in the Order, except as to jurisdiction, which it admitted, EPIX consented to the entry of an Order Making Findings and Revoking Registration of Securities Pursuant to Section 12(j) of the Securities Exchange Act of 1934 as to EPIX Pharmaceuticals, Inc. finding that it had failed to comply with Section 13(a) of the Securities Exchange Act of 1934 (Exchange Act) and Rules 13a-1 and 13a-13 there under and revoking the registration of each class of EPIX's securities pursuant to Section 12(j) of the Exchange Act. This order settled the charges brought against EPIX in In the Matter of Diomed Holdings, Inc., et al., Administrative Proceeding File No. 3-15047.
SEC Orders Hearing On Registration Suspension Or Revocation Against EPIX Pharmaceuticals
Sep 27 12
In conjunction with trading suspension, the Securities and Exchange Commission (SEC) also instituted public administrative proceeding to determine whether to revoke or suspend for a period not exceeding twelve months the registration of each class of the securities of EPIX Pharmaceuticals, Inc. for failure to make required periodic filings with the Commission. In this Order, the Division of Enforcement (Division) alleges that the company is delinquent in its required periodic filings with the Commission. In this proceeding, instituted pursuant to Exchange Act Section 12(j), a hearing will be scheduled before an Administrative Law Judge. At the hearing, the judge will hear evidence from the Division and the company to determine whether the allegations of the Division contained in the Order, which the Division alleges constitute failures to comply with Exchange Act Section 13(a) and Rules 13a-1 and 13a-13 there under, are true. The judge in the proceeding will then determine whether the registrations pursuant to Exchange Act Section 12 of each class of the securities of the company should be revoked or suspended for a period not exceeding twelve months. The Commission ordered that the Administrative Law Judge in this proceeding issue an initial decision not later than 120 days from the date of service of the order instituting proceeding.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries